Join the Fight Against MDS

Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.

Viewing: Patient & VisitorPatient & Visitor HCPHealthcare Professional

December 6, 2024

MDS 2024: Let’s Overcome the Challenges

Claim Credits

Program Overview

The MDSF ASH 2024 Symposium will focus on challenges the MDS community faces in 2024. Progress has been made in understanding the biology, genetics and pathogenesis of MDS. Prognostication, and treatment strategies have been improved, but not satisfactorily. In 2024 we are still facing problems: Can we assess minimal residual disease? We are still debating regarding the recommended Hb threshold for RBC transfusions. The increasing role of inflammation in the disease pathogenesis, raises the question of anti-inflammatory treatment. The reports on germline mutations and their role in MDS in adulthood might change our genetic screening policy. Finally, we are still puzzled whether patients with higher-risk disease should be treated with hypomethylating agents only, as the only proven treatment, or additional therapy might improve the outcome. The symposium will highlight these challenges, and based on recent advances in the field, potential solutions will be presented and discussed.

Target Audience

This activity is designed for an audience of nurses, pharmacists, physicians, and physician associates.

Learning Objectives

Participants will learn about novel information obtained over the last decade and will hear about potential applications in the field of MDS.

More specifically practitioners and researchers:

Attendees will learn about MRD in MDS
They will face the question of liberal vs restrictive RBC transfusion policy, and what’s next or in addition to RBC transfusions in LR-MDS
They will become familiar with the role of inflammation in the pathogenesis of the disease and the potential application of MDS anti-inflammatory treatment.
The symposium participants will hear about germline mutations and the dilemma of whom of the family members or others should be screened for mutations.
They will attend the debate whether to continue treating patients with HR-MDS with hypomethylating agents only or should we prefer combination treatments.
Patient discussion will complete the educational lessons by combining scientific evidence with practical real-life issues. These discussion will focus on patients with LR- and HR-MDS

Claim Your Credits for Attending the Symposium!

Thank you for joining us at the event on Friday, December 6, 2024. If you attended, you may be eligible to claim credits.

Claim Credits

Speakers

Lionel Adès, MD, PhD

Rena Buckstein, MD, FRCPC

Aristoteles Giagounidis, MD

Jaroslaw Maciejewski, MD, PhD, FACP

Moshe Mittelman, MD

Ghulam J. Mufti, MD, FRCP, FRCPath

Stephen D. Nimer, MD

Esther Oliva, MD

Casey L. O’Connell, MD

Magnus Tobiasson, MD, PhD

Lachelle Weeks, MD, PhD

Presentation Recordings

Access to the meeting presentations are available below by clicking on each topic.

Our Supporters

Thank you to Agios Pharmaceuticals, Inc, Bristol-Myers Squibb, Geron Corporation, Keros Therapeutics, Notable, Rigel Pharmaceuticals, Inc, and Taiho Oncology for supporting this initiative.

Program Overview

Learning Objectives

Participants will learn about novel information obtained over the last decade and will hear about potential applications in the field of MDS.

More specifically practitioners and researchers:

Attendees will learn about MRD in MDS

They will face the question of liberal vs restrictive RBC transfusion policy, and what’s next or in addition to RBC transfusions in LR-MDS

They will become familiar with the role of inflammation in the pathogenesis of the disease and the potential application of MDS anti-inflammatory treatment.

The symposium participants will hear about germline mutations and the dilemma of whom of the family members or others should be screened for mutations.

They will attend the debate whether to continue treating patients with HR-MDS with hypomethylating agents only or should we prefer combination treatments.

Patient discussion will complete the educational lessons by combining scientific evidence with practical real-life issues. These discussion will focus on patients with LR- and HR-MDS

Join the Fight Against MDS

MDS 2024: Let’s Overcome the Challenges

Program Overview

Target Audience

Learning Objectives

Claim Your Credits for Attending the Symposium!

Speakers

Presentation Recordings

Welcome

Challenges in MDS – 2024

Using MRD to Guide Treatment in MDS

Debate I: The Approach for RBC Transfusion Policy

Patient Discussion

Debate II: A Role for Anti-Inflammatory Treatment

Who Should be Tested for the Presence of Myeloid Predisposition Mutations?

Debate III: Treatment of HR-MDS (in 2024)

Closing Remarks

Our Supporters

Get in touch

Join the Fight Against MDS

MDS 2024: Let’s Overcome the Challenges

Program Overview

Target Audience

Learning Objectives

Claim Your Credits for Attending the Symposium!

Speakers

Presentation Recordings

Welcome

Challenges in MDS – 2024

Using MRD to Guide Treatment in MDS

Debate I: The Approach for RBC Transfusion Policy

Patient Discussion

Debate II: A Role for Anti-Inflammatory Treatment

Who Should be Tested for the Presence of Myeloid Predisposition Mutations?

Debate III: Treatment of HR-MDS (in 2024)

Closing Remarks

Our Supporters

Join the Fight Against MDS

MDS 2024: Let’s Overcome the Challenges

Program Overview

Target Audience

Learning Objectives

Claim Your Credits for Attending the Symposium!

Speakers

Presentation Recordings

WelcomeStephen D. Nimer, MD

Welcome

Challenges in MDS – 2024Moshe Mittelman, MD

Challenges in MDS – 2024

Using MRD to Guide Treatment in MDSMagnus Tobiasson, MD, PhD

Using MRD to Guide Treatment in MDS

Debate I: The Approach for RBC Transfusion PolicyRena Buckstein, MD, FRCPCEsther Oliva, MD

Debate I: The Approach for RBC Transfusion Policy

Patient DiscussionLionel Adès, MD, PhDRena Buckstein, MD, FRCPCGhulam J. Mufti, MD, FRCP, FRCPath

Patient Discussion

Debate II: A Role for Anti-Inflammatory TreatmentLachelle Weeks, MD, PhDLionel Adès, MD, PhD

Debate II: A Role for Anti-Inflammatory Treatment

Who Should be Tested for the Presence of Myeloid Predisposition Mutations?Jaroslaw Maciejewski, MD, PhD, FACP

Who Should be Tested for the Presence of Myeloid Predisposition Mutations?

Debate III: Treatment of HR-MDS (in 2024)Ghulam J. Mufti, MD, FRCP, FRCPathAristoteles Giagounidis, MD

Debate III: Treatment of HR-MDS (in 2024)

Closing RemarksCasey L. O’Connell, MD

Closing Remarks

Our Supporters

Get in touch

Join the Fight Against MDS

MDS 2024: Let’s Overcome the Challenges

Program Overview

Target Audience

Learning Objectives

Claim Your Credits for Attending the Symposium!

Speakers

Presentation Recordings

WelcomeStephen D. Nimer, MD

Welcome

Challenges in MDS – 2024Moshe Mittelman, MD

Challenges in MDS – 2024

Using MRD to Guide Treatment in MDSMagnus Tobiasson, MD, PhD

Using MRD to Guide Treatment in MDS

Debate I: The Approach for RBC Transfusion PolicyRena Buckstein, MD, FRCPCEsther Oliva, MD

Debate I: The Approach for RBC Transfusion Policy

Patient DiscussionLionel Adès, MD, PhDRena Buckstein, MD, FRCPCGhulam J. Mufti, MD, FRCP, FRCPath

Patient Discussion

Debate II: A Role for Anti-Inflammatory TreatmentLachelle Weeks, MD, PhDLionel Adès, MD, PhD

Debate II: A Role for Anti-Inflammatory Treatment

Who Should be Tested for the Presence of Myeloid Predisposition Mutations?Jaroslaw Maciejewski, MD, PhD, FACP

Who Should be Tested for the Presence of Myeloid Predisposition Mutations?

Debate III: Treatment of HR-MDS (in 2024)Ghulam J. Mufti, MD, FRCP, FRCPathAristoteles Giagounidis, MD

Debate III: Treatment of HR-MDS (in 2024)

Closing RemarksCasey L. O’Connell, MD

Closing Remarks

Our Supporters